Post-earnings recap
Reported
Thu, May 2, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that PTC Therapeutics faced challenges in meeting EPS expectations, which may raise concerns among investors. However, the stock reacted positively, increasing by nearly 3% on the day. This could suggest that investors are optimistic about the company's ongoing clinical trials and future product developments despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.29 | N/A | -73.92% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their clinical programs. They did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.